Publikationen

Prof. Dr. med. M. Edinger TP 1
Ausgewählte Publikationen der Jahre 2000-2009

1. Schmidl C, Klug M, Boeld TJ, Hoffmann P, Edinger M , Rehli M. Li neage-specific DNA methylation in T cells correlates with histone methylation and enhancer activity (eingereicht).

2. Xiao-nong Wang, Muzlifah A Haniffa, Udo Holtick, Matthew P Collin, Graham Jackson, Catharien MU Hilkens, Ernst Holler, Matthias Edinger , Petra Hoffmann, Anne M Dickinson. Natural regulatory T cell suppression of human CD8+ T cell mediated graft-versus-host reaction requires their presence during priming. BMT (in press).

3. Hoffmann P, Boeld TJ, Eder R, Huehn J, Floess S, Wieczorek G, Olek S, Dietmaier W, Andreesen R, Edinger M. Loss of FOXP3 expression in natural human CD4+CD25+ regulatory T cells upon repetitive in vitro stimulation. Eur. J. Immunol. (Epub Mar 12, 2009)

4. Edinger M , Powrie F, Chakraverty R. (2008). Regulatory mechanisms in graft-versus-host responses. Biol Blood Marrow Transplant, 15(1):2-6.

5. Edinger M (2008). CD4+CD25+ regulatory T cells approach the clinic. Cytotherapy 10(7):655.

6. Fowler D, Hoffmann P & M Edinger . Functionally defined T cell subsets in transplantation biology and therapy: regulatory T cells and Th2 cells (in "Hematopoietic Stem Cell Transplantation, Ed. MR Bishop, Springer 2008).

7. Baron U, Floess S, Wieczorek G, Baumann K, Gruetzkau A, Dong J, Thiel A, Boeld TJ, Hoffmann P, Edinger M , Tuerbachova I, Hamann A, Olek S & J Huehn (2007). DNA demethylation in the human FOXP3 locus discriminates regularoy T cells from activated FOXP3+ conventional T cells. Eur J Immunol. 37 ( 9 ): 2378-89 .

8. Fischer K, Hoffmann P, Voelkl S, Meidenbauer N, Ammer J, Edinger M , Gottfried E, Schwarz S, Rothe G, Hoves S, Renner K, Timischl B, Mackensen A, Kunz-Schughardt L, Andreesen R, Krause SW Kreutz M (2007). Inhibitory effect of tumor cell derived lactic acid on human T cells. Blood 109(9): 3812-9.

9. Hoffmann P, Eder R, Boeld TJ, Doser K, Piseshka B, Andreesen R & M Edinger (2006). Only the CD45RA + subpopulation of CD4 + CD25 high T cells gives rise to homogeneous regulatory T cell lines upon in vitro expansion. Blood 108(13):4260-7.

10. Greinix, HT, Socie, G, Bacigalupo A, Holler E, Edinger M , Apperley JF, Schwarz T, Ullrich SE, Albert ML, Knobler RM, Peritt D & JL Ferrara (2006). Assessing the potential role of photopheresis in hematopoietic stem cell transplant. Bone Marrow Transplant. 38(4):265-73.

11. Hoffmann P, Boeld TJ, Eder R, Piseshka B, Dada A, Niemand C, Assenmacher M, Orso E, Andreesen R, Holler E & M Edinger (2006). Isolation of CD4 + CD25 high regulatory T cells for clinical trials, Biol. Blood & Marrow Transpl. 12(3): 267-74.

12. Hoffmann P. & M Edinger (2006) CD4 + CD25 + regulatory T cells and graft-versus-host disease, Semin Hematol . 43(1): 62-69.

13. Hoffmann, P., Boeld, T.J., Piseshka, B. & M. Edinger (2005). Immunomodulation after allogeneic bone marrow transplantation by CD4+CD25+ regulatory T cells. Microbes Infect 7: 1066-1072 .

14. Hoffmann, P, Ermann, J. & M. Edinger (2005). CD4+CD25+ regulatory T cells in allogeneic stem cell transplantation. Curr. Topic Microbiol. & Immunol . 293: 265-285.

15. Verneris, M.R., Arshi, A., Edinger, M. , Kornacker, M., Natkunam, Y., Karami, M., Cao, Y., Marina , N., Contag, C and R. Negrin (2005). Ewing 's family tumor cell lines express low levels of Her2/neu which can be used as a target to redirect ex vivo activated and expanded T cells . Clin. Cancer Res. 11: 4561-4570.

16. Leemhuis, T., Wells, S., Scheffold, C., Edinger, M ., Negrin, R. (2005). A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkins disease and non-Hodgkin lymphoma Biol Blood Marrow Transpl . 11:181-187.

17. Ermann, J., Hoffmann, P., Edinger, M ., Dutt, S., Higgins, J., Negrin, R.S., Fathman, C.G., Strober, S. (2005). Only the CD62L+ subpopulation of CD4+CD25+ regulatory T cells protects from lethal acute GVHD. Blood, 105: 2220-2226

18. Hoffmann, P., Eder, R., Kunz-Schughart, L.A., Andreesen, R., Edinger, M. (2004). Large scale in vitro expansion of polyclonal human CD4+CD25high regulatory T cells. Blood 104: 895-903.

19. Edinger, M (2004). Immunoregulation in human bone marrow transplantation? Inside Blood Editorial, Blood 104:1920.

20. Mandl, S., Mari, C ., Edinger, M. , Negrin, R.S., Tait, J.F., Contag, C.H., Blankenberg, F (2004). In vivo dynamics of cell death in a mouse model of lymphoma: Multi-modality imaging identifies key imaging times for assessing response to chemotherapy. Molecular Imaging 3(1): 1-8.

21. Edinger, M., Hoffmann, P., Ermann, J., Drago, K., Fathman, C.G., Strober, S., Negrin, R.S. (2003). CD4 + CD25 + regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus host disease after bone marrow transplantation. Nature Medicine, 9(9), 1144-50 .

22. Edinger, M., Hoffmann, P., Contag, C.H., Negrin, R.S. (2003). Evaluation of effector cell fate and function by in vivo bioluminescence imaging. Methods , 31(2), 172-79.

23. Edinger, M., Cao, Y., Verneris, M.R., Bachmann, M.H., Contag, C.H., Negrin, R.S (2003). Revealing lymphoma growth and the efficacy of immune cell therapies using bioluminescence in vivo imaging. Blood 101(2), 640-8.

24. Hoffmann, P., Ermann, J., Edinger, M., Fathman, C.G., Strober, S. (2002). Donor type CD4 + CD25 + T cells suppress lethal acute graft versus host disease after allogeneic bone marrow transplantation. J. Exp. Med. 196(3), 389-99.

25. Edinger, M. , Cao, Y.A., Hornig, Y.S., Jenkins, D.E., Verneris, M.R., Bachmann, M.H., Negrin, R.S., Contag, C.H. (2002). Advancing animal models of neoplasia through in vivo bioluminescence imaging. Eur. J. Cancer 38(16), 2128-36.

26. Negrin, R.S., Edinger, M. , Verneris, M., Cao, Y.A., Bachmann, M., Contag, C.H. (2002). Visualization of tumor growth and response to NK-T cell based immunotherapy using bioluminescence. Ann. Hematol. 81, Suppl. 2, 44-45.

27. Mandl, S., Schimmelpfennig, C., Edinger, M. , Negrin, R.S., Contag, C.H. (2003). Understanding immune cell trafficking patterns via in vivo bioluminescence imaging. J. Cell. Biochem., Suppl, 39: 239-248 .

28. Verneris, M.R., Baker, J., Edinger, M. , Negrin, R.S. (2002). Studies of ex vivo activated and expanded CD8+ NK-T cells in humans and mice. J. Clin. Immunol. 22(3), 131-6.

29. Hardy, J., Edinger, M ., Bachmann, M., Negrin, R.S., Fathman, G.C., Contag, C.H. (2001). Bioluminescence imaging of lymphocyte trafficking in vivo . Exp. Hematol . 29, 1353-1360.

30. Edinger, M ., Sweeney, T.J., Tucker, A.A., Olomu, A.B., Negrin, R.S., Contag, C.H. (1999). Non-invasive assessment of tumor cell proliferation in animal models. Neoplasia 1: 303-310.

31. Hoffmann P, Eder R, Boeld TJ, Doser K, Piseshka B, Andreesen R, Edinger M.
Only the CD45RA+ subpopulation of CD4+CD25high T cells gives rise to homogeneous regulatory T-cell lines upon in vitro expansion. Blood. 2006 Dec 15;108(13):4260-7. Epub 2006 Aug 17.
Link zu PubMed

32. Hoffmann P, Boeld TJ, Eder R, Albrecht J, Doser K, Piseshka B, Dada A, Niemand C, Assenmacher M, Orso E, Andreesen R, Holler E, Edinger M.
Isolation of CD4+CD25+ regulatory T cells for clinical trials. Biol Blood Marrow Transplant. 2006 Mar;12(3):267-74.
Link zu PubMed


33. Hoffmann P, Edinger M.
CD4+CD25+ regulatory T cells and graft-versus-host disease. Semin Hematol. 2006 Jan;43(1):62-9. Review.
Link zu PubMed

 

Dr. rer. nat. P. Hoffmann, TP 3
Ausgewählte Publikationen der Jahre 2003-2009

1. Schmidl C., M. Klug, T.J. Boeld, R. Andreesen, P. Hoffmann , M. Edinger, M. Rehli. 2009. Lineage-specific DNA methylation in T cells correlates with histone methylation and enhancer activity. (eingereicht Genome Research; in Revision).

2. Xiao-nong Wang, M. A Haniffa, U. Holtick, M. P Collin, G. Jackson, C.M.U. Hilkens, E. Holler, M. Edinger, P. Hoffmann , A. M. Dickinson. 2009. Natural regulatory T cell suppression of human CD8+ T cell mediated graft-versus-host reaction requires their presence during priming. Transplantation (im Druck).

3. Hoffmann P. , T. J. Boeld, R. Eder, J. Huehn, S. Floess, G. Wieczorek, S. Olek, M. Dietmaier, R. Andreesen, and M. Edinger. 2009. Loss of FOXP3 expression in natural human CD4 + CD25 + regulatory T cells upon repetitive in vitro stimulation. Eur J Immunol (im Druck; e-pub ahead of print: 12. März 2009)

4. Baron U., S. Floess, G. Wieczorek, K. Baumann, A. Grützkau, J. Dong, A. Thiel, T. J. Boeld, P. Hoffmann , M. Edinger, I. Türbachova, A. Hamann, S. Olek, and J. Huehn. 2007. DNA demethylation in the human FOXP3 locus discriminates Tregs from activated FOXP3+ conventional T cells. Eur J Immunol 37:2378-89.

5. Fischer K., P. Hoffmann , S. Voelkl, N. Meidenbauer, J. Ammer, M. Edinger, E. Gottfried, S. Schwarz, G. Rothe, S. Hoves, K. Renner, B. Timischl, A. Mackensen, L. Kunz-Schughart, R. Andreesen, S.W. Krause, and M. Kreutz. 2007. Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood 109:3812-9.

6. Hoffmann P., R. Eder, T.J. Boeld, K. Doser, B. Piseshka, R. Andreesen, and M. Edinger. 2006. Only the CD45RA+ subpopulation of CD4+CD25high T cells gives rise to homogeneous regulatory T cell lines upon in vitro expansion. Blood 108:4260-7.

7. Hoffmann, P. , T.J. Boeld, R. Eder, B. Piseshka, J. Albrecht, K. Doser, A. Dada, C. Niemand, M. Assenmacher, E. Orso, R. Andreesen, E. Holler, M. Edinger. 2006. Isolation of CD4+CD25+ regulatory T cells for clinical trials. Biol Blood Marrow Transplant. 12:267-274.

8. Hoffmann, P. , M. Edinger. 2006. CD4 + CD25 + regulatory T cells and graft-versus-host disease. Semin Hematol. 43:62-9 .

9. Hoffmann, P ., T.J. Boeld, B. Piseshka, M. Edinger. Immunomodulation after allogeneic bone marrow transplantation by CD4 + CD25 + regulatory T cells. 2005. Microbes Infect . 7: 1066-1072

10. Hoffmann, P ., J. Ermann, M. Edinger. CD4+CD25+ regulatory T cells in allogeneic stem cell transplantation. 2005. Curr. Topic Microbiol. & Immunol 293:265-285 .

11. Ermann, J., P. Hoffmann , M. Edinger, S. Dutt, F.G. Blankenberg, J.P. Higgins, R.S. Negrin, C.G. Fathman, S. Strober . 2005. Only the CD62L+ subpopulation of CD4+CD25+ regulatory T cells protects from lethal acute GVHD. Blood 105:2220-6 .

12. Merad, M., P. Hoffmann , E. Ranheim, S. Slaymaker, M.G. Manz, S.A .Lira, I. Charo, D.N. Cook, I.L. Weissman, S. Strober, and E.G. Engleman. 2004. Depletion of host Langerhans cells before transplantation of donor alloreactive T cells prevents skin graft-versus-host disease. Nat.Med. 10:510-517

13. Hoffmann, P. , R. Eder, L.A. Kunz-Schughart, R. Andreesen, and M. Edinger. 2004. Large Scale In Vitro Expansion of Polyclonal Human CD4+CD25high Regulatory T Cells. Blood 104:895-903 .

14. Zeng, D., F. Lan, P. Hoffmann , and S. Strober. 2004. Suppression of graft-versus-host disease by naturally occurring regulatory T cells. Transplantation 77:S9-S11.

15. Edinger, M., P. Hoffmann , J. Ermann, K. Drago, C.G. Fathman, S. Strober, and R.S. Negrin. 2003. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat.Med. 9:1144-1150.

16. Edinger, M., P. Hoffmann , C.H. Contag, and R.S. Negrin. 2003. Evaluation of effector cell fate and function by in vivo bioluminescence imaging. Methods 31:172-179.

17. Hoffmann, P. , J. Ermann, M. Edinger, C.G. Fathman, and S. Strober. 2002. Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J.Exp.Med. 196:389-399.

 

Prof. Dr. med. A. Mackensen TP 4

1. Grube M, Moritz S, Obermann EC, Rezvani K, Mackensen A, Andreesen R, Holler E.
CD8+ T cells reactive to survivin antigen in patients with multiple myeloma. Clin Cancer Res. 2007 Feb 1;13(3):1053-60.
Link zu PubMed

2. Fischer K, Hoffmann P, Voelkl S, Meidenbauer N, Ammer J, Edinger M, Gottfried E, Schwarz S, Rothe G, Hoves S, Renner K, Timischl B, Mackensen A, Kunz-Schughart L, Andreesen R, Krause SW, Kreutz M.
Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood. 2007 May 1;109(9):3812-9. Epub 2007 Jan 25.
Link zu PubMed

3. Blank C, Mackensen A.
Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion. Cancer Immunol Immunother. 2007 May;56(5):739-45. Epub 2006 Dec 29.
Link zu PubMed


4. Walton SM, Gerlinger M, de la Rosa O, Nuber N, Knights A, Gati A, Laumer M, Strauss L, Exner C, Schafer N, Urosevic M, Dummer R, Tiercy JM, Mackensen A, Jaeger E, Levy F, Knuth A, Jager D, Zippelius A.
Spontaneous CD8 T cell responses against the melanocyte differentiation antigen RAB38/NY-MEL-1 in melanoma patients. J Immunol. 2006 Dec 1;177(11):8212-8.
Link zu PubMed

5. Mackensen A, Meidenbauer N, Vogl S, Laumer M, Berger J, Andreesen R.
Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma. J Clin Oncol. 2006 Nov 1;24(31):5060-9.
Link zu PubMed


6. Fischer K, Voelkl S, Berger J, Andreesen R, Pomorski T, Mackensen A.
Antigen recognition induces phosphatidylserine exposure on the cell surface of human CD8+ T cells. Blood. 2006 Dec 15;108(13):4094-101. Epub 2006 Aug 15.
Link zu PubMed

7. Blank C, Kuball J, Voelkl S, Wiendl H, Becker B, Walter B, Majdic O, Gajewski TF, Theobald M, Andreesen R, Mackensen A.
Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro. Int J Cancer. 2006 Jul 15;119(2):317-27.
Link zu PubMed


8. Gottfried E, Kunz-Schughart LA, Ebner S, Mueller-Klieser W, Hoves S, Andreesen R, Mackensen A, Kreutz M.
Tumor-derived lactic acid modulates dendritic cell activation and antigen expression. Blood. 2006 Mar 1;107(5):2013-21. Epub 2005 Nov 8.
Link zu PubMed



Prof. Dr. med. M. Fleck TP 5
Ausgewählte Publikationen der Jahre 2003-2008

1. Hoves S, Krause SW, Halbritter D, Zhang HG, Mountz JD, Schölmerich J, Fleck M . Mature but not immature human monocyte-derived Dendritic Cells transduced by Fas Ligand (CD95L) are protected from Fas-mediated apoptosis and can be used as Killer APC. J. Immunol. 2003: 170:5406-5413

2. Ichikawa K, Liu W, Fleck M , Zhang HG, Zhao L, Ohtsuka T, Wang Z, Liu D, Mountz JD, Ohtsuki M, Koopman WJ, Kimberly R, Zhou T: TRAIL-R2 (DR5) mediates apoptosis of synovial fibroblasts in rheumatoid arthritis. J. Immunol. 2003;171:1061-1069

3. Hoves S, Krause SW, Schölmerich J, Fleck M . The JAM-assay: optimized conditions to determine death receptor-mediated apoptosis. Methods 2003;31: 127-134

4. Hoves S, Krause SW, Halbritter D, Zhang HG, Mountz JD, Schölmerich J, Fleck M . Elimination of activated but not resting primary human CD4 + and CD8 + T cells by CD95 ligand (FasL)-expressing Killer-DC. Immunobiol. 2004;208, 463-475

5. Harangi M, Kaminski WE, Fleck M , Orso E, Zeher M, Kiss E, Szekanecz Z, Zilahi E, Marienhagen J, Aslanidis C, Paragh J, Jonsson R, Schmitz G. Homozygosity for the 168His variant of the minor histocompatibility antigen HA-1 is associated with reduced risk of primary Sjögren's syndrome. Eur. J. Immunol, 2005;35:305-317

6. Paul G, Bataille F, Obermeier F, Klebl F, Strauch, Lochbaum D, Rümmele P, Farkas S, Schölmerich J, Fleck M , Rogler G, Herfarth H. Analysis of intestinal heme-oxygenase-1 (HO-1) in clinical and experimental colitis. Clin. Exp. Immunol., 2005;140:547-555

7. Merk JD, Schmidt, FX, Fleck M , Schwarz S, Lehane C, Boehm S, Salzberger B, Birnbaum E. Fatal pulmonary failure due to viral pneumonia with Human Herpers Virus 6 (HHV6) in a young immunocompetent woman. J. Inten. Care Med. 2005;20:302-306.

8. Lindner J, Barabas S, Saar K, Altmann D, Pfister A, Fleck M , Deml L, Modrow S. CD4+ T-cell responses against the VP1-unique region in individuals with recent and persistent parvovirus B19 infection. Vet. Med. B. Infect. Dis. Vet. Public Health 2005;52:356-361

9. Weigert J, Neumeier M, Schäffler A, Fleck M , Schölmerich J, Schütz C, Büchler C. The adiponectin paralog CORS-26 has anti-inflammatory properties and is produced by human monocytic cells . FEBS Lett. 2005;579:5565-5570

10. Härle P, Ehrenstein BP, Fleck M , Glück T, Herold T, Schubert TEO, Straub RH, Schölmerich J. A patient with arthritis, severe back pain, impaired wound healing and perforated sigma. Lancet 2006;367:2032  

11. Mühlbauer M , Fleck M , Schütz C, Weiss TS, Froh M, Blank C, Schölmerich J, Hellerbrand C. PD-L1 is induced in hepatocytes by viral infection and IFN-a and IFN-g and mediates T cell apoptosis. J Hepatol., 2006;45:520-528  

12. Hoves S, Krause SW, Schütz C, Halbritter D, Schölmerich J, Herfarth H, Fleck M . Monocyte-derived human macrophages mediate anergy in T cells and induce regulatory T cells. J. Immunol. 2006;177:2691-2698

13. Schwemmer S, Beer P, Schölmerich J, Fleck M , Straub RH. Cardiovascular and pupillary autonomic nervous dysfunction in patients with rheumatoid arthritis - a cross-sectional and longitudinal study. Clin. Exp. Rheumatology 2006;24:683-689

14. Buhl A, Metzger JH, Heegaard NH, von Landenberg P, Fleck M , Luppa PB. Novel biosensor-based analytic device for the detection of anti-double-stranded DNA antibodies. Clin. Chem. , 2007;53:334-341
Link zu PubMed

15. Siebig S, Tarner IH, Wrede C, Schölmerich J, Müller-Ladner U, Fleck M . A case of recurrent abdominal bleeding due to polyarteritis nodosa despite immunsuppressive therapy. Scand. J. Rheumatol., 2007;36:486-488 .

16. Schütz C, Fleck M , Mackensen A, Zoso A, Halbritter D, Schneck JP, Oelke M. Killer-artificial-antigen-presenting-cells (KaAPC): a novel strategy to delete specific T cells. Blood 2008; 111:3546-3552

17. Resch M, Schichtl T, Endemann DH, Griese DP, Kasprzak P, Djavidani B, Fleck M , Luchner A, Riegger GA. General aneurysmatosis due to cheese consumption: Complications of an endocarditis caused by Lactococcus cremoris. Int. J. Cardiol. 2008;126:e8-9

18. Straub RH, Pongratz P, Härle P, Fleck M , Cutolo M, Atzeni F, Antoni C, Gruenke M, Kalden JR, Schölmerich J, Lorenz HM, Sarzi-Puttini P. Increased cortisol relative to adrenocorticotropic hormone predicts improvement during anti-tumor necrosis factor therapy in rheumatoid arthritis. Arthritis Rheum., 2008;58:976-984

19. Maier J, Birkenfeld G, Pfirstinger J, Schölmerich J , Fleck M , Brühl H. Effective treatment of steroid refractory adult-onset Still's disease with anakinra as a first line immunosuppressive therapy. J. Rheumatol., 2008; 35:939-941

20. Teichmann LL, Woenckhaus M, Salzberger B, Schölmerich J, Fleck M . Fatal Pneumocystis pneumonia in a patient suffering from rheumatoid arthritis following rituximab administration. Rheumatology, 2008;47:1256-1257

21. Judex A, Hartung W, Schölmerich J, Fleck M . Hypothyroidism with Leading Myopathy in a Patient Suffering from Systemic Lupus Erythematosus and Hashimoto's Thyroiditis. Med. Klin. 2008;103:731-735.

22. Maier J, Hartung W, Pfeifer M, Härle P, Schölmerich J, Fleck M . Effective treatment of Rheumatoid Arthritis-associated Interstitial Lung Disease by B-cell targeted therapy with Rituximab. Zur Publikation eingereicht .

23. Schütz C, Fischer K, Völkl S, Hoves S, Halbritter D, Mackensen A, Fleck M . A New Flow Cytometric Assay for the Simultaneous Analysis of Antigen Specific Elimination of T Cells in Heterogenous T Cell Populations. Zur Publikation eingereicht.

 

Prof. Dr. E. Geissler, TP 6
BIBLIOGRAPHY-Journal Articles (2005-present):

1. Schnitzbauer AA, Lamby PE, Mutzbauer I, Zuelke C, Schlitt HJ, Geissler EK. (2009) Ethical review for clinical trials within the EU: a harmonised procedure? Brit Med J (in press).

2. Koehl GE, Gaumann A, Geissler EK . (2009) Intravital microscopy of tumor angiogenesis and regression in the dorsal skin fold chamber: mechanistic insights and preclinical testing of therapeutic strategies. Clin Exp Metastasis Feb. 4. [Epub ahead of print].

3. Geissler EK , Schlitt HJ. (2009) Imunnosuppression for liver trans­plantation. Gut . 58: 452-463.

4. Hutchinson JA, Gövert F, Riquelme P, Bräsen JH, Brem-Exner BG, Matthai M, Schulze M, Renders L, Kunzendorf U, Geissler EK , Fändrich F. (2008) Case Report: Administration of donor-derived transplant acceptance-inducing cells to the recipients of renal transplants from deceased donors is technically feasible. Clin Transplant. 23:140-145.

5. Lang SA, Moser C, Fichnter-Feigl S, Schachtschneider P, Hellerbranc C, Schmitz V, Schlitt HJ, Geissler EK, Stoeltzing O. (2009) Targeting heat-shock protein 90 improves efficacy of rapamycin in a model of hepatocellular carcinoma in mice. Hepatology 49:523-532.

6. Fichtner-Feigl S, Strober W, Geissler EK , Schlitt HJ. (2008) Cytokines mediating the induction of chronic colitis and colitis-associated fibrosis. Mucosal Immunol . Suppl 1:24-27.

7. Lang SA, Schachtschneider P, Moser C, Mori A, Hackl C, Gaumann A, Batt D, Schlitt HJ, Geissler EK , Stoeltzing O. (2008) Dual targeting of Raf and VEGF receptor 2 reduces growth and metastasis of pancreatic cancer through direct effects on tumor cells, endothelial cells, and pericytes. Mol Cancer Ther. 7:3509-3518.

8. Alexander S, Koehl GE, Hirschberg M, Geissler EK , Friedl P. (2008) Dynamic imaging of cancer growth and invasion: a modified skin-fold chamber model. Histochem Cell Biol. 130:1147-1154

9. Fichtner-Feigl F, Young CA, Kitani A, Geissler EK , Schlitt HJ, Strober W. (2008) IL-13 signaling via IL-13 Signaling via IL13Ralpha(2) induces major downstream fibrogenic factors mediating fibrosis in chronic TNBS colitis. Gastroenterology 135:2003-2013 .

10. Geissler EK , Schlitt HJ, Thomas G. (2008) mTOR, cancer and trans­plantation. Am J Transplant. 8:2212-2218.

11. Popp FC, Eggenhofer E, Renner P, Slowik P, Lang SA, Kaspar H, Geissler EK , Piso P, Schlitt HJ, Dahlke MH. (2008) Mesenchymal stem cells can induce long-term acceptance of solid organ allografts in synergy with low-dose mycophenolate. Transpl Immunol. 8:55-60.

12. Eggenhofer E, Popp FC, Renner P, Slowik P, Neuwinger A, Piso P, Geissler EK , Schlitt HJ, Dahlke MH. (2008) Allogeneic bone marrow transplantation restores liver function in Fah-knockout mice. Exp Hematol. 36:1513-1519.

13. Moser C, Lang SA, Mori A, Hellerbrand C, Schlitt HJ, Geissler EK, Fogler WE, Stoeltzing O. (2008) ENMD-1198, a novel tubulin-binding agent reduces HIF-1alpha and STAT3 activity in human hepatocellular carcinoma (HCC) cells, and inhibits growth and vascularization in vivo. BMC Cancer . 8:206.

14. Hutchinson JA, Riquelme P, Brem-Exner BG, Schulze M, Matthäi M, Renders L, Kunzendorf U, Geissler EK , Fändrich F. (2008) Transplant acceptance-inducing cells as an immune-conditioning therapy in renal transplantation. Transpl Int. 21:728-741.

15. Hutchinson JA, Brem-Exner BG, Riquelme P, Roelen D, Schulze M, Ivens K, Grabensee B, Witzke O, Philipp T, Renders L, Humpe A, Sotnikova A, Matthäi M, Heumann A, Gövert F, Schulte T, Kabelitz D, Class FH, Geissler EK , Kunzendorf U, Fändrich F. (2008) A cell-based approach to the minimization of immunosuppression in renal trans­plantation. Transpl Int. 21:742-754

16. Hutchinson JA, Roelen D, Riquelme P, Brem-Exner BG, Witzke O, Philipp T, Matthäi M, Gövert F, Claas FH, Westphal E, Kunzendorf U, Geissler EK , Fändrich F. (2008) Preoperative treatment of a presensitized kidney transplant recipient with donor-derived transplant acceptance-inducing cells. Transpl Int. 21:808-813.

17. Fichtner-Feigl S, Terabe M, Kitani A, Young CA, Fuss I, Geissler EK , Schlitt HJ, Berzofsky JA, Strober W. (2008) Restoration of tumor immunosurveillance via targeting of interleukin-13 receptor-alpha 2. Cancer Res. 68:3467-3475.

18. Moser C, Schachtschneider P, Lang SA, Gaumann A, Mori A, Zimmermann J, Schlitt HJ, Geissler EK , Stoeltzing O. (2008) Inhibition of insulin-like growth factor-I receptor (IGF-IR) using NVP-AEW541, a small molecule kinase inhibitor, reduces orthotopic pancreatic cancer growth and angiogenesis. Eur J Cancer . 44: 1577-1586.

19. Doenecke A, Frank E, Scherer MN, Schlitt HJ, Geissler EK . (2008) Prolongation of heart allograft survival after long-term expression of soluble MHC class I antigens and vIL-10 in the liver by AAV-plasmid-mediated gene transfer. Langenbecks Arch Surg. 393:343-348.

20. Lang SA, Brecht I, Moser C, Obed A, Batt D, Schlitt HJ, Geissler EK, Stoeltzing O. (2008) Dual inhibition of Raf and VEGFR2 reduces growth and vascularization of hepatocellular carcinoma in an experimental model. Langenbecks Arch Surg. 393:333-341.

21. Gaumann A, Schlitt HJ and Geissler EK . (2008) Immunosupression and tumor development in organ transplant recipients: the emerging dualistic role of rapamycin. Transpl Int. 21:207-217.

22. Kabelitz D, Geissler EK , Soria B, Schroeder IS, Faendrich F, Chatenoud L. (2008) Toward cell-based therapy of type I diabetes. Trends Immunol. 29:68-74.

23. Brem-Exner BG, Sattler C, Hutchinson JA, Koehl GE, Kronenberg K, Farkas S, Inoue S, Blank C, Knechtle SJ, Schlitt HJ, Faendrich F and Geissler EK . (2008) Macrophages driven to a novel state of activation have anti-inflammatory properties in mice. J Immunol. 180:335-349.

24. Moser C, Lang SA, Kainz S, Gaumann A, Fichtner-Feigl S, Koehl GE, Schlitt HJ, Geissler EK , Stoeltzing O. (2007) Blocking heat shock protein 90 inhibits invasive properties and hepatic growth of human colon cancer cells and improves efficacy of oxaliplatin in p53-deficient colon cancer tumors in vivo. Mol Cancer Ther. 6:2868-2878.

25. Lang SA, Moser C, Gaumann A, Klein D, Glockzin G, Popp FC, Dahlke MH, Piso P, Schlitt HJ, Geissler EK , Stoeltzing O. (2007) Targeting Hsp90 in pancreatic cancer impairs insulin-like growth factor-I receptor signaling, disrupts an IL-6/STAT3/HIF-1 a autocrine loop, and reduces orthotopic tumor growth. Clin Cancer Res. 13:6459-6468

26. Conrad C, Ischenko I, Köhl G, Wiegand U, Guba M, Yezhelyev M, Ryan M, Barge AJ, Geissler EK, Wedge SR, Jauch KW, Bruns CJ. (2007) Antiangiogenic and antitumor activity of a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor ZD6474 in a metastatic human pancreatic tumor model. Anticancer Drugs. 18:569-579.

27. Koehl GE, Geissler EK , Iacobelli M, Frei C, Burger V, Haffner S, Holler E, Andreesen R, Schlitt HJ, and Eissner G. (2007) Defibrotide: an endothelium protecting and stabilizing drug, has an anti-angiogenic potential in vitro and in vivo. Cancer Biol Ther. 6:686-690.

28. Fichtner-Feigl S, Fuss IJ, Young CA, Watanabe T, Geissler EK , Schlitt HJ, Kitani A and Strober W. (2007) Induction of IL-13 triggers TGF-b1-dependent tissue fibrosis in chronic TNBS-colitis. J Immunol. 178:5859-5870.
Link zu PubMed

29. Lang SA, Gaumann A, Koehl GE, Seidel U, Bataille F, Klein D, Ellis LM, Bolder U, Hofstaedter F, Schlitt HJ, Geissler EK and Stoeltzing O. (2007) Mammalian target of rapamycin (mTOR) is activated in human gastric cancer and serves as a target for therapy in an experimental model. Int J Cancer. 120:1803-1810.
Link zu PubMed

30. Lang SA, Klein D, Moser C, Gaumann A, Glockzin G, Dahlke MH, Dietmaier W, Bolder U, Schlitt HJ, Geissler EK , Stoeltzing O. (2007) Inhibition of heat shock protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo. Mol Cancer Ther. 6:1123-1132.
Link zu PubMed

31. Popp FC, Slowik P, Eggenhofer E, Renner P, Lang SA, Stoeltzing O, Geissler EK , Piso P, Schlitt HJ and Dahlke MH. (2007) No contribution of multipotent mesenchymal stromal cells to liver regeneration in a rat model of prolonged hepatic injury, Stem Cells , 25:639-645.
Link zu PubMed

32. Koehl GE, Wagner F, Stoeltzing O, Lang SA, Steinbauer M, Schlitt HJ and Geissler EK . (2007) Mycophenolate mofetil inhibits tumor growth and angiogenesis in vitro but has variable antitumor effects in vivo, possibly related to bioavailability. Transplantation 83:607-614.
Link zu PubMed

33. Jäger MD, Liu JY, Timrott KF, Popp FC, Stoeltzing O, Lang SA, Piso P, Geissler EK , Schlitt HJ and Dahlke MH. (2007) Sirolimus promotes tolerance for donor and recipient antigens after MHC class II disparate bone marrow transplantation in rats. Exp Hematol. 35:164-170.
Link zu PubMed

34. Farkas S, Hornung M, Sattler C, Guba M, Steinbauer M, Anthuber M, Herfarth H, Schlitt HJ and Geissler EK . (2006) Rapamycin decreases leukocyte migration in vivo and effectively reduces experimentally-induced chronic colitis Int J Colorectal Dis. 21:747-75 3.

35. Koehl GE, Gaumann A, Zuelke C, Hoehn A, Hofstaedter F, Schlitt HJ and Geissler EK (2006) Development of de novo cancer in p53 knock-out mice is dependent on the type of long-term immunosuppression used. Transplantation. 82:741-748.
Link zu PubMed

36. Inoue S, Popp FC, Koehl GE, Piso P, Schlitt HJ, Geissler EK and Dahlke MH. (2006) Immunomodulatory effects of mesenchymal stem cells in a rat organ transplant model. Transplantation. 81:1589-1595.
Link zu PubMed

37. Hornung M, Farkas SA, Sattler C, Schlitt HJ and Geissler EK . (2006) DX5+NKT cells induce the death of colitis-associated cells: involvement of PD-L1. Eur J Immunol. 36:1210-1221.
Link zu PubMed

38. Farkas S, Hornung M, Sattler C, Edtinger K, Steinbauer M, Fuerst A, Anthuber M, Schlitt HJ, Herfarth H and Geissler EK . (2006) Blocking MAdCAM-1 in vivo reduces leukocyte extravasation and reverses chronic inflammation in experimental colitis. Int J Colorectal Dis. 21:71-78.
Link zu PubMed

39. Farkas S, Hornung M, Sattler C, Anthuber M, Gunthert U, Herfarth H, Schlitt HJ, Geissler EK and Wittig BM. (2005) Short-term treatment with anti-CD44v7 antibody, but not CD44v4, restores the gut mucosa in established chronic dextran sodium sulfate (DSS)-induced colitis in mice. Clin Exp Immunol. 142:260-267.

40. Meyer S, Hafner C, Guba M, Flegel S, Geissler EK , Becker B, Koehl GE, Orso E, Landthaler M and Vogt T. (2005) Ephrin-B2 over­expression enhances integrin-mediated ECM-attachment and migration of B16 melanoma cells. Int J Oncol. 27:1197-1206.

41. Rentsch M, Puellmann K, Sirek S, Iesalnieks I, Kienle K, Mueller T, Bolder U, Geissler EK , Jauch KW and Beham A. (2005) Benefit of Kupffer cell modulation with glycine versus Kupffer cell depletion after liver transplantation in the rat: effects on postischemic reperfusion injury, apoptotic cell death, regeneration and survival. Transpl Int. 18:1079-1089.

42. Guba M, Yezhelyev M, Eichhorn M, Schmid G, Ischenko I, Papyan A, Graeb C, Seeliger H, Geissler EK , Jauch KW and Bruns CJ. (2005) Rapamycin induces tumor-specific thrombosis via tissue factor in the presence of VEGF. Blood. 105:4463-4469.

43. Farkas S, Hornung M, Sattler C, Steinbauer M, Anthuber M, Obermeier F, Herfarth H, Schlitt HJ and Geissler EK (2005). Preferential Migration of CD62L+ Cells into the Appendix in Mice with Experimental Chronic Colitis. Eur Surg Res. 37:115-122.

44. Farkas S, Bolder U, Schlittenbauer T, Obed A, Zuelke C, Anthuber M, EK Geissler and Schlitt HJ (2005). Conditioning of liver grafts with prostaglandins improves bile acid transport. Transplant Proc. 37:435-438.

45. Guba M, Koehl GE, Neppl E, Doenecke A, Steinbauer M, Jauch KW and Geissler EK . (2005) Dosing of rapamycin is critical to achieve an optimal antiangiogenic effect against cancer. Transpl Int. 18:89-94.

46. Koehl GE, Schlitt HJ and Geissler EK . (2005) Rapamycin and tumor growth: mechanisms behind its anti-cancer activity. Transpl Reviews . 19:20-31.

47. von Breitenbuch P, Koehl G, Guba M, Geissler EK, Jauch KW and Steinbauer M. (2005) Thermoablation of colorectal liver metastases promotes proliferation of residual intrahepatic neoplastic cells. Surgery. 138:882-887.

 

PD Dr. F. Obermeier, TP 7
Ausgewählte Publikationen der Jahre 2004-2009

1. Schultz M, Strauch UG, Linde HJ, Watzl S, Obermeier F , Gottl C, Dunger N, Grunwald N, Schölmerich J, Rath HC:
Preventive effects of Escherichia coli strain Nissle 1917 on acute and chronic intestinal inflammation in two different murine models of colitis.
Clin Diagn Lab Immunol 2004;11:372-378. (IF: 2,056)

2. Stopfer P, Obermeier F , Dunger N, Falk W, Farkas S, Janotta M, Moller A, Mannel DN, Hehlgans T:Blocking lymphotoxin-beta receptor activation diminishes inflammation via reduced mucosal addressin cell adhesion molecule-1 (MAdCAM-1) expression and leucocyte margination in chronic DSS-induced colitis.
Clin Exp Immunol 2004;136:21-29. (IF: 2,599)

3. Hausmann M, Obermeier F , Schreiter K, Spottl T, Falk W, Schölmerich J, Herfarth H, Saftig P, Rogler G:
Cathepsin D is up-regulated in inflammatory bowel disease macrophages.
Clin Exp Immunol 2004;136:157-167. (IF: 2,599)

4. Weiss TS, Herfarth H, Obermeier F , Ouart J, Vogl D, Schölmerich J, Jauch KW, Rogler G:
Intracellular polyamine levels of intestinal epithelial cells in inflammatory bowel disease.
Inflamm Bowel Dis 2004;10:529-535 (IF: 4,705)

5. Farkas SA, Hornung M, Sattler C, Steinbauer M, Anthuber M, Obermeier F , Herfarth H, Schlitt HJ, Geissler EK:
Preferential migration of CD62L cells into the appendix in mice with experimental chronic colitis.
Eur Surg Res 2005;37:115-122. (IF: 0,755)

6. Paul G, Bataille F, Obermeier F , Bock J, Klebl F, Strauch U, Lochbaum D, Rummele P, Farkas S, Schölmerich J, Fleck M, Rogler G, Herfarth H :
Analysis of intestinal haemoxygenase-1 (HO-1) in clinical and experimental colitis.
Clin Exp Immunol 2005;140:547-555. (IF: 2,599)

7. Obermeier F , Strauch UG, Dunger N, Grunwald N, Rath HC, Herfarth H, Schölmerich J, Falk W:
In vivo CpG DNA/toll-like receptor 9 interaction induces regulatory properties in CD4+CD62L+ T cells which prevent intestinal inflammation in the SCID transfer model of colitis.
Gut 2005;54:1428-1436. (IF: 10,015)

8. Strauch UG, Obermeier F , Grunwald N, Guerster S, Dunger N, Schultz M, Griese DP, Maehler M, Schölmerich J, Rath HC:
Influence of intestinal bacteria on induction of regulatory T-cells: lessons from a transfer model of colitis. Gut 2005; 54:1546-52. (IF: 10,015)

9. Obermeier F , Dunger N, Strauch UG, Hofmann C, Bleich A, Grunwald N, Hedrich HJ, Aschenbrenner E, Schlegelberger B, Rogler G, Schölmerich J, Falk W:
CpG motifs of bacterial DNA essentially contribute to the perpetuation of chronic intestinal inflammation.
Gastroenterology 2005;129:913-927. (IF: 11,673)

10. Obermeier F , Herold T, Schönberger J, Eilles C, Glück T, Kullmann F, Schölmerich J, Tarner I, Müller-Ladner U:
Vasculitis of the aortic arch and cardiac valves as cause of relapsing fever of unknown origin in an elderly, caucasian male.
Clin.Rheumatol. 2006 Nov;25(6):923-5 (IF: 1,261)

11. Schacherer D, Wrede C, Obermeier F , Schlottmann K, Schölmerich J, Klebl F:
Comparison of low and high frequency transducers in the detection of liver metastases.
Digestive Liver Disease, 2006; 38(9):677-82 (IF: 1,818)

12. Reber S, Obermeier F , Werner F, Straub RH, Chronic intermittent psycho-social stress in mice increases the severity of an acute DSS induced colitis and additionally impairs regeneration, Endocrinology, 2006;147(10):4968-76. (IF: 5,045)

13. Lock G, Dirscherl M, Obermeier F , Gelbmann CM, Hellerbrand C, Knöll A, Schölmerich J, Jilg W:Hepatitis C - contamination of toothbrushes: myth or reality?.
J Viral Hepat . 2006; 13(9):571-3. (IF: 2,550)

14. Herfarth H, Tjaden C, Lukas M, Obermeier F , Dilger K, Müller R, Schölmerich J.
Adverse events in clinical trials with azathioprine and mesalamine for prevention of postoperative recurrence of Crohn's disease.
Gut 2006; 55(10):1525-6. (IF: 10,015)

15. Obermeier F , Hausmann M, Kellermeier S, Kiessling S, Strauch UG, Duitman E, Bulfone-Paus S, Herfarth HH, Bock J, Dunger N, Stoeck M, Schölmerich J, Falk W, Rogler G:
Interleukin 15 (IL-15) Protects Intestinal Epithelial Cells (IEC).
Eur J Immunol . 2006; 36(10):2691-9 (IF: 4,662)

16. Menzel K, Hausmann M, Obermeier F , Schreiter K, Dunger N, Bataille F, Falk W, Schölmerich J, Herfarth H, Rogler G:
Cathepsins B, L and D in inflammatory bowel disease macrophages and potential therapeutic effects of cathepsin inhibition in vivo.
Clin Exp Immunol . 2006;146(1):169-80. (IF: 2,599)

17. Reber SO, Birkeneder L, Obermeier F , Veenema AH, Falk W, Straub RH, Neumann ID:
Adrenal insufficiency and colonic inflammation after a novel chronic psycho social stress paradigm in mice: implications and mechanisms.
Endocrinology. 2007; 148(2):670-82. (IF: 5,045)

18. Hofmann C, Obermeier F , Artinger M, Hausmann M, Falk W, Schölmerich J, Rogler G, Grossmann J:
Cell-cell contacts prevent anoikis in primary human colonic epithelial cells.
Gastroenterology. 2007; 132(2):587-600. (IF: 11,673)

19. von Delius S, Eckel F, Wagenpfeil S, Mayr M, Stock K, Kullmann F, Obermeier F , Erdmann J, Schmelz R, Quasthoff S, Adelsberger H, Schmid RM, Lersch C:
Carbamazepine does not prevent Oxaliplatin-Related Neuro-toxicity in Patients with Advanced Colorectal Cancer: Results of a Randomised, Controlled, Multicenter Phase II Study.
Invest New Drugs . 2007; 25(2):173-80. (IF: 2,417)

20. Ewaschuk J, Backer LJ, Churchill A, Obermeier F , Madsen K: Surface expression of TLR9 on intestinal epithelial cells is upregulated in response to pathogenic bacterial DNA.
Infect Immun. 2007; 75(5):2572-9. (IF: 3,996)

21. Hausmann M and Obermeier F (equal contribution) , Paper DH, Balan K, Menzel K, Falk W, Schoelmerich J, Herfarth H, Rogler G:
In vivo treatment with the herbal phenylethanoide acteoside ameliorates intestinal inflammation in dextran sulphate sodium (DSS)-induced colitis.
Clin Exp Immunol. 2007;148(2):373-81. (IF: 2,599)

22. Strauch UG, Obermeier F , Grunwald N, Dunger, Rath HC, Schölmerich J, Steinmeyer A, Zügel U, Herfarth HH:
The vitamin D3 analogue ZK191784 ameliorates acute and chronic DSS-induced colitis by inhibition of dendritic cell activation.
World J Gastroenterol. 2007;13(48):6529-37.

23. Lippert E, Gunckel M, Brenmoehl J, Bataille F, Falk W, Obermeier F , Rogler G:
Regulation of galectin-3-function in mucosal fibroblasts: potential role in IBD.
Clin Exp Immunol 2008; 152(2):285-97. (IF: 2,599)

24. Ott C, Obermeier F , Thieler S, Kemptner D, Bauer A, Schölmerich J, Rogler G, Timmer A:
The incidence of inflammatory bowel disease in a rural region of Southern Germany - a prospective population based study.
Eur J Gastroenterol Hepatol . 2008; 20(9):917-23. (IF: 2,599)

25. Hafner S, Timmer A, Herfarth H, Schoelmerich J, Schaeffler A, Jilg W, Ehrenstein B, Strauch UG, Rogler G, Obermeier F :
The role of domestic hygiene in Inflammatory Bowel Diseases: Hepatitis A and Worm Infestations.
Eur J Gastroenterol Hepatol . 2008; 20(6):561-6. (IF: 1,830)

26. Reber SO, Obermeier F , Falk W, Straub RH, Neumann ID:
Aggravation of DSS-induced colitis after chronic subordinate colony (CSC) housing is partially mediated by adrenal mechanisms.
Stress 2008;11(3):225-34.

27. Veenema AH, Reber S, Selch S, Obermeier F , Neumann ID:
Early life stress enhances the vulnerability to chronic psychosocial stress and experimental colitis in adult mice
Endocrinology 2008;149(6):2727-36(IF: 5,045)

28. Straub RH, Grum F, Strauch U, Capellino S, Bataille F, Bleich A, Falk W, Schölmerich J, Obermeier F
Anti-inflammatory role of sympathetic nerves in chronic intestinal inflammation
Gut 2008;57(7):911-21. (IF: 10,015)

29. Schubert T, Obermeier F , Ugocsai P, Männel D, Echtenacher B, Hofstädter F, Härle P:
Murine models of anemia of inflammation: extramedullary hematopoiesis represents a species specific difference to human anemia of inflammation that can be eliminated by splenectomy.
Int J Immunopathol Pharmacol 2008; 21(3):577-84. (IF: 4,665)

30. Guralnik V, Schäffler A, Schölmerich J, Schlitt HJ, Müller-Wille R, Feuerbach S, Obermeier F :
Partial splenic artery embolization for the treatment of a patient with hypersplenism due to liver cirrhosis
Dtsch Med Wochenschr 2008;133(38):1893-6. (IF: 0,433)

31. Sander LE, Obermeier F , Dierssen U, Kroy DC, Singh AK, Seidler U, Streetz KL, Lutz HH, Müller W, Tacke F, Trautwein C:
Gp130 signaling promotes development of acute experimental colitis by facilitating early neutrophil/macrophage recruitment and activation
J Immunol 2008;181(5):3586-94. (IF: 6,068)

32. Gäbele E, Mühlbauer M, Dorn C, Weiss TS, Froh M, Schnabl B, Wiest R, Schölmerich J, Obermeier F , Hellerbrand C:
Role of TLR9 in hepatic stellate cells and experimental liver fibrosis
Biochem Biophys Res Commun 2008;14:376(2):271-6. (IF: 2,749)

33. Bleich A, Janus LM, Smoczek A, Westendorf AM, Strauch U, Mähler M, Hedrich HJ, Fichtner-Feigl S, Schölmerich J, Falk W, Hofmann C, Obermeier F :
CpG Motifs of Bacterial DNA Exert Protective Effects in Mouse Models of IBD by Antigen-Independent Tolerance Induction
Gastroenterology 2009;Jan;136(1):278-87). (IF: 11,673)

34. Blaas SH, Stieber-Gunckel M, Falk W, Obermeier F, Rogler G.:
CpG-oligodeoxynucleotides stimulate immunoglobulin A secretion in intestinal mucosal B cells.
Clin Exp Immunol . 2009 Mar;155(3):534-40. (IF: 2,599)

35. Timmer A, Obermeier F:
Reduced risk of ulcerative colitis after appendicectomy. BMJ . 2009 Mar 9;338:b225 (IF: 9,723)

36. Bauer J, Huy C, Brenmoehl J, Obermeier F, Bock J.
Matrix metalloproteinase-1 expression induced by IL-1beta requires acid sphingomyelinase. FEBS Lett . 2009 Mar 4;583(5):915-20 (IF: 3,263)